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Abstract Evidence is provided that human skin, the largest body 
organ exposed to multiple stressors, expresses proopiomelano- 
cortin (POMC), corticotropin releasing hormone (CRH) and 
CRH-receptor (CRHR) genes in vivo. In vitro studies show that 
POMC and CRHR mRNAs are transcribed in melanocytes, cells 
derived from the neural crest, and in keratinocytes, cells derived 
from the ectoderm. CRH mRNA is transcribed in cultured mela- 
nocytes but not in keratinocytes. It is proposed that an equivalent 
of the 'hypothalamus-pituitary axis' composed of the CRH- 
CRHR-POMC loop is conserved in mammalian skin. 
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1. Introduction 
Skin is the largest body organ that is directly and perma- 
nently exposed to multiple physical, chemical and biological 
influences. Therefore, the skin should be able to respond imme- 
diately by generating appropriate signals for defense against 
these stressors and to reestablish tissue homeostasis. The first 
and at present best understood step in response to stress by the 
organism is the activation of the hypothalamus-pituitary-axis 
[1 3]. It starts with an induction of CRH production in the 
hypothalamus, which after delivery to the pituitary activates 
CRH receptors [2]. This cascade culminates with an increased 
expression of POMC and secretion of POMC peptides [3]. 
Recent reports documented that the skin is not only a target 
for POMC peptide (MSH, ACTH and fl-endorphin) bioregula- 
tion but also a site of POMC gene expression itself [4]. Cutane- 
ous POMC expression was demonstrated in the skin of C57 
BL/6 mice [5] and in rodent melanomas [6]. Furthermore, it was 
shown that the human epidermal carcinoma cell line A431 
expresses POMC, and that this expression was enhanced by 
exposure of cells to UVB or phorbol mirystate acetate (PMA) 
[7]. In vivo, localized and cell restricted accumulation of 
POMC-derived ACTH,  fl-endorphin and f l -MSH was demon- 
strated in human skin biopsies both under pathologic and phys- 
iologic conditions [8]. Although these data suggested that accu- 
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mulation of POMC products may arise from local production 
due to normal skin reactivity or disease-related phenomena, 
experiments demonstrating POMC mRNA expression in 
human skin remained to be performed [8]. Moreover we de- 
cided to test whether CRH and CRHR genes are expressed in 
human skin. 
2. Materials and methods 
2.1. Skin biopsies and cell culture 
Skin biopsy samples were obtained from patients een at the Albany 
Medical College. Routine histopathologic analyses were performed in 
sections stained with hematoxylin-eosin. For molecular analyses the 
tissues were frozen in liquid nitrogen. Human pituitaries were obtained 
from the National Hormone and Pituitary Program, National Institute 
of Diabetes, Digestive and Kidney Diseases (NIDDKD). 
Semiconfluent cultures of foreskin human melanocytes and ker- 
atinocytes were grown in Ham's FI0 medium supplemented with 5% 
fetal calf serum, 85 nM 12-O-tetradecanoylphorbol-13 acetate (TPA), 
0.1 mM isobutylmethylxanthine (IBMX), 1 mM insulin and 40/lg 
bovine pituitary extract (GIBCO, NY) and in keratinocyte-SFM sup- 
plemented with growth factors (GIBCO, NY), respectively [9]. Human 
melanocytes and keratinocytes were cultured in 75 cm ~ flasks without 
any treatment or were treated either with the UVB at 25 mJ/cm 2 or 100 
nM TPA [9]. 
2.2. Reverse transcription-polymerase chain reaction (RT-PCR) 
assays 
Total RNA from frozen tissue and cells was extracted using the 
RNAzol B isolation kit following the manufacturer's protocol 
(CINNA/BIOTECX Laboratories, Houston, TX). For the RT-PCR 
assays 2/lg of total RNAs were reverse transcribed using oligo(dT) as 
primers and the Superscript preamplification system (GIBCO-BRL, 
Gaithersburg, MD). Only samples that were proven to be free from 
DNA contamination by running PCR amplification without prior RT 
were used for the experiments. Fragments derived from the coding 
regions of human POMC [10], CRH [11] and CRH-R [12,13] cDNAs 
were amplified using primers designed and synthetized commercially 
(National Bioscience, Plymouth, MN). The reaction mixtures con- 
tained 25 mM (NH4)2SO4 buffer, pH 9.0 (POMC cDNA) or pH 9.5 
(CRH-R and CRH cDNAs), 2 mM MgCl 2, 0.4 mM dNTP and 4 ¢tM 
of primers. The cDNAs were heated at 94°C for 3 min and then 
amplified. The PCR products were separated on 1.5% agarose, stained 
with ethidium bromide and photographed under UV light. 
2.3. Southern blot hybridization 
Specificity of the amplified products in all cases was proven by 
hybridization of the RT-PCR products with cDNAs corresponding to
the analysed gene, i.e. POMC, CRH or CRHR as described below. 
After denaturation i 0.5 M NaOH and 1.5 M NaCI, products of 
RT-PCR were transferred to nylon membranes (Oncor, Gaithersburg, 
MD) and UV crosslinked to the membranes. Membranes were prehy- 
bridized in Hybridizol I (Oncor, Gaithersburg, MD) at 42°C for 4 h 
and hybridized with [~-3Zp]dCTP-labelled human cDNAs for an addi- 
tional 15 h at 42°C. After washing with 2 x SSC plus 0. 1% SDS at room 
temperature and with 0.1 x SSC plus 0.1% SDS at 60°C membranes 
were exposed on Kodak XAR film at -70°C. 
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carcinoma nd in pigmented skin lesions [8]. Thus, human skin 
has the capability to transcribe and translate the POMC gene, 
and the keratinocytes and melanocytes are the potential source 
of POMC peptides in vivo. 
POMC expression and processing are under stimulatory con- 
trol, mediated mainly by CRH through the activation of CRH 
receptors [1-3]. With the use of coding sequences of the CRH 
gene cloned from the human brain [11] and CRHR cloned from 
the human pituitary and brain [12, 13], primers for RT-PCR 
assays were designed (cf. Figures legend). The expression of 
CRH mRNA in human skin biopsies from the scalp, compound 
nevus and basal call carcinoma is shown in Fig 2A. The RT- 
PCR assay demonstrated the predicted 413 bp product repre- 
sentative of the CRH exon 2 transcript (Fig. 2A) that hybrid- 
ized to human CRH cDNA and was absent in RNA amplified 
A 1 2 3 4 5 6 
260 bp--~ 
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Fig. 1. POMC gene expression in human skin. (A) RT-PCR detection 
of 260 bp product representative ofPOMC exon 3 mRNA (arrow) in 
skin biopsies. Size markers (bp) (1), compound nevus (2), basal cell 
carcinoma (3), human scalp skin (4), pollution control (reaction mixture 
without DNA template) (5). (B) RT-PCR detection of 260 bp product 
representative of POMC exon 3 mRNA (arrow) in cultured mela- 
nocytes and keratinocytes. Pituitary (1), pollution control (reaction 
mixture without DNA template) (2), DNA size markers of 700, 525, 
500, 400 and 300 bp (3), melanocytes (4), amplified RNA from mela- 
nocytes without prior RT (control) (5), keratinocytes (6), amplified 
RNA keratinocytes without prior RT (control) (7). RT-PCR detection 
was done using sense primer, 5'-GAG GGC AAG CGC TCC TAC 
TCC-Y (nucleotides (nt) 605 to 625) and antisense primer, 5'-GGG 
GCC CTC GTC CTT CTT CTC-Y (nt 845 to 865) for the human 
POMC cDNA [10]. The PCR program was 30 cycles of 45 s at 95°C, 
1 rain at 58°C and 2 min at 72°C with final extension of 7 min at 72°C. 
B 1 2 3 4 5 6 7 8 9 
3. Results and discussion 
In the present study, using reverse transcription polymerase 
chain reaction (RT-PCR) (30 cycles), we demonstrated that the 
POMC gene is expressed in human skin in vivo, e.g. in normal 
scalp, compound nevus and basal cell carcinoma (Fig. 1A). The 
predicted 260 bp product is specific for exon 3 of the POMC 
gene. It is absent in control RNA samples that have been 
amplified without previous reverse transcription, and it hybrid- 
ized to the POMC cDNA (not shown). Using cultured in vitro 
normal human melanocytes and keratinocytes, we detected by 
RT-PCR the 260 bp specific product representative of exon 3 
of the POMC mRNA (Fig. 1B). The presence of POMC 
mRNA correlates with previous detection of ACTH, fl-MSH 
and fl-endorphin immunoreactivity n human scalp, basal cell 
Fig. 2. Expression ofCRH gene in human skin. Arrow shows a 413 bp 
product representative ofmRNA from the CRH coding region ofexon 
2 [l 1]. (A) Pituitary control (1), DNA size markers of 700, 525, 500, 400, 
300 and 200 bp (2), pollution control (reaction mixture without DNA 
template) (3), compound nevus (4), basal cell carcinoma (5), human 
scalp skin (6). (B) Pituitary control (1), pollution control (reaction 
mixture without DNA template) (2), DNA size markers (3); untreated 
melanocytes (4), melanocytes treated with UVB 25 mJ/cm z (5), mela- 
nocytes treated with 100 nM of TPA (6); untreated keratinocytes (7), 
keratinocytes treated with UVB 25 mJ/cm 2 (8), keratinocytes treated 
with 100 nM of TPA (9). RT-PCR detection was done using sense 
primer, 5'-CAC CCT CAG CCC TTG GAT TTC-Y (nt 1436 to 1456) 
and antisense primer, 5'-GCC CTG GCC ATT TCC AAG AC-3' (nt 
1828 to 1848) for the CRH cDNA [11]. The PCR program was 35 cycles 
of 30 s at 96°C, 30 s at 55°C and 2 min at 72°C with final extension 
of 7 min at 72°C. 
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Fig. 3. Expression of CRHR gene in human skin. (A) RT-PCR detec- 
tion of 334 bp (arrow) and of 400 bp (arrowhead) products representa- 
tive of CRHR mRNA. From the left: DNA size markers (bp), RT-PCR 
products from compound nevus (1), basal cell carcinoma (2) and human 
scalp skin (3), PCR amplified RNA without prior RT from compound 
nevus (4), basal cell carcinoma (5) and human scalp skin (6). (B) RT- 
PCR detection of 334 bp (arrow) product representative of CRHR 
mRNA. Pituitary control (1), untreated melanocytes (2), melanocytes 
treated with UVB at 25 mJ/cm 2 (3), untreated keratinocytes (4), ker- 
atinocytes treated with UVB at 25 mJ/cm 2 (5). RT-PCR was done using 
sense primer, 5'-GCC CTG CCC TGC CTT TTT CTA-Y (nt 424 to 
444) and antisense primer, 5'-GCT CAT GGT TAG CTG GAC CA-3' 
(nt 738 to 757) for the coding region of the CRHR cDNA [12,13]. The 
PCR program was 35 cycles of 45 s at 95°C, 1 min at 58°C and 2 min 
at 72°C with final extension of 7 min at 72°C. The RT-PCR products 
were separated on a 1.5% agarose gel, blotted to nylon membranes and 
hybridized to 3Zp-labelled CRHR cDNA. 
without RT (not shown). The RT-PCR of RNA isolated from 
human cultured cells showed the CRH gene expression i  mela- 
nocytes but not in keratinocytes (Fig. 2B). Thus, the human 
skin should be added to the growing list of peripherial organs 
that express differentially CRH gene in vivo [2]. 
Using the RT-PCR and primers for the coding region of the 
CRHR cDNA, we detected two products in skin biopsies (Fig. 
3A). One had a size of 334 bp (arrow) corresponding to pre- 
dicted size of the pituitary CRHR cDNA fragment and was 
expressed in a compound nevus, a basal cell carcinoma nd 
normal human scalp skin (Fig. 3A). The second one was larger 
(400 bp product marked by arrowhead) and was expressed in 
the scalp only (Fig. 3A). We suggest hat both fragments are 
115 
representative of the CRHR transcript(s) because they were 
absent in corresponding RNA amplified without RT and they 
hybridized to the CRHR cDNA (Fig. 3A). The smaller frag- 
ment represents he CRHR mRNA of the gene cloned from the 
pituitary [12,13]. The larger fragment (arrowhead, Fig. 3A) may 
represent either alternatively spliced CRI-IR mRNA or an addi- 
tional member of the CRHR family. Additional members of the 
CRHR family that are expressed by peripherial tissues have 
been identified [14,15], and some of the cloned genes produce 
alternatively spliced CRHR mRNAs [13-15]. Furthermore, the 
anagen hair follicle of the scalp is a miniorgan with the highest 
mitotic activity in the body generated by a coordinated interac- 
tion of epithelial, mesenchymal cells and melanocytes as well 
as by a local skin immune system [16]. Therefore, it is likely that 
more than one CRHR gene can be expressed by different cell 
populations depending on the developmental status of the skin. 
To identify cells expressing the CRHR gene we tested mela- 
nocytes and keratinocytes cultured in vitro that had been ex- 
posed to UVB. The predicted 343 bp message characteristic for 
the human pituitary (positive control, lane 1) that hybridized 
to the CRHR cDNA was detected in UVB treated melanocytes 
(lane 3) and keratinocytes (lane 5) but was absent in untreated 
melanocytes (lane 2) and keratinocytes (lanes 4) (Fig. 3B). This 
inducible gene expression suggests that expression of the 
CRHR can be an additional control point of the organized skin 
response to UVB, which already involves an increased produc- 
tion of POMC mRNA, ACTH and ~-MSH peptides as well as 
~-MSH receptors by malignant melanocytes and keratinocytes 
cultured in vitro [9]. 
The presented ata show for the first time that the control 
points of the 'hypothalamus-pituitary axis', POMC, CRH and 
CRHR genes are expressed in human skin. The cell-type re- 
stricted CRH mRNA expression i  melanocytes and the induc- 
ible expression of CRHR mRNA in melanocytes and ker- 
atinocytes uggest a tight regulation of the CRH-CRHR- 
POMC loop through an autocrine (melanocyte) and paracrine 
(melanocyte versus keratinocyte) mechanism. These findings 
are not surprising taking into consideration the size of the skin, 
its anatomical distribution and functional diversity. The skin, 
because of its continous exposure to variable stressors must 
have a rapid, local and efficient mechanism of defense and of 
stabilization of tissue homeostasis. In this context, a local 
CRH-CRHR-POMC loop would represent a more economical 
and optimal defense program than reliance on the centrally 
driven hypothalamus-pituitary-axis. 
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